Company information - Ordinary shares of Hepalys (Details) € / shares in Units, € in Thousands, $ in Millions |
12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Oct. 11, 2023
shares
|
Sep. 29, 2023
USD ($)
|
Sep. 26, 2023
¥ / shares
|
Sep. 26, 2023
€ / shares
|
Sep. 20, 2023
¥ / shares
|
Sep. 20, 2023
€ / shares
|
Dec. 31, 2025
EUR (€)
|
Dec. 31, 2024
EUR (€)
|
Dec. 31, 2023
EUR (€)
|
|
| Collaborative Arrangements | |||||||||
| Issue of equity | € | € 284,621 | € 57,338 | € 30,587 | ||||||
| Hepalys Pharma, Inc | |||||||||
| Collaborative Arrangements | |||||||||
| Issue of equity | $ | $ 13 | ||||||||
| Group's share in % | 15.00% | 15.00% | 15.00% | 15.00% | |||||
| Catalys Option Agreement | Hepalys Pharma, Inc | |||||||||
| Collaborative Arrangements | |||||||||
| Number of shares acquired in associate | shares | 1,500,000 | ||||||||
| Option to acquire shares in company, percentage | 30.00% | 30.00% | 30.00% | 30.00% | |||||
| Purchase of interests in investments accounted for using equity method, price per share | (per share) | ¥ 300 | € 1.9 | ¥ 300 | € 1.9 | |||||